title: Inducible nitric oxide synthase inhibition influenced granuloma formation with suppressed collagen expression in myositis caused by Toxocara canis in mice.
abstract: The role of nitric oxide (NO) in granuloma pathology is largely unclear to date. We investigated the role of NO in fibrotic granuloma development in the musculature of mice infected with Toxocara canis from 1 day (dpi) to 8 weeks post-infection (wpi) using the NO synthase (NOS) inhibitors, L-NIL (l-N6-1-iminoethyl lysine). In infected mice, elevated serum NO concentrations were seen at 1 dpi (204.1 +/- 0.2 microM) and 1 wpi (145.1 +/- 0.2 microM); it declined drastically from 4 wpi onwards (57.0 +/- 0.1 microM). In L-NIL-treated mice, the NO concentration was drastically reduced from 15% during 1 wpi; thereafter, it was restored to almost half that in infected mice. Inducible NOS expression was enhanced in infected and L-NIL-treated mice at 4 wpi but declined at 8 wpi as assessed by immunohistochemistry. L-NIL treatment resulted in large, irregularly shaped granulomas with suppressed collagen contents at 4 wpi but not at 8 wpi. The suppressed collagen contents might have been related to decreased serum NO and Th2-type cytokine of interleukin-4 but not Th1-type cytokine of interferon-gamma expression.
authors.affiliation: Department of Pathology and Laboratory Medicine, Shin-Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan.
authors.forename: Su-Mei
authors.initials: SM
authors.lastname: Lin
authors.forename: Chien-Wei
authors.initials: CW
authors.lastname: Liao
authors.forename: Yun-Ho
authors.initials: YH
authors.lastname: Lin
authors.forename: Chin-Cheng
authors.initials: CC
authors.lastname: Lee
authors.forename: Ting-Chang
authors.initials: TC
authors.lastname: Kao
authors.forename: Chia-Kwung
authors.initials: CK
authors.lastname: Fan
mesh_terms: D000818:Animals; D003094:Collagen / Q000037:antagonists & inhibitors* / Q000378:metabolism; D004791:Enzyme Inhibitors / Q000008:administration & dosage / Q000494:pharmacology; D006099:Granuloma / Q000469:parasitology / Q000473:pathology / Q000503:physiopathology*; D008239:Lysine / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000494:pharmacology; D051379:Mice; D009220:Myositis / Q000276:immunology / Q000469:parasitology / Q000473:pathology / Q000503:physiopathology; D009569:Nitric Oxide / Q000097:blood / Q000378:metabolism*; D052247:Nitric Oxide Synthase Type II / Q000037:antagonists & inhibitors*; D017166:Toxocara canis / Q000472:pathogenicity*; D014120:Toxocariasis / Q000276:immunology / Q000469:parasitology / Q000473:pathology / Q000503:physiopathology
chemical_list: D004791:Enzyme Inhibitors; C090663:N(6)-(1-iminoethyl)lysine; D009569:Nitric Oxide; D003094:Collagen; D052247:Nitric Oxide Synthase Type II; D008239:Lysine